IWG-defined hematologic improvement by cell lineage in patients with MDS
. | . | . | % response,*major (minor) . | . | . | ||
|---|---|---|---|---|---|---|---|
| Treatment . | No. patients . | % IPSS/FAB . | HI-E . | % HI-P . | % HI-N . | ||
| Lenalidomide21 | 43 | Low, 51; Int1, 37; Int2, 9; High, 2 | 49 (7) | 10 | 17 | ||
| Darbepoetin alfa24 | 40 | Low, 38; Int1, 52; Int2, 10 | 47 (12) | 0 | 0 | ||
| Antithymocyte immunoglobulin25 | 20 | RA, 65; RARS, 15; RAEB, 20 | 45 (5) | 35 (10) | 10 (5) | ||
| Antithymocyte immunoglobulin26 | 68 | RA, 53; RARS, 4; RAEB, 11 | 67 (20) | 40 (27) | 27 (7) | ||
| Cyclosporine A27 | 50 | Low, 8; Int1, 82; Int2, 10 | 34 (16) | 16 (12) | 22 (4) | ||
| Thalidomide28 | 83 | Low/Int1, 70; High/Int2, 30 | 13 (5) | 0 (1) | 0 | ||
| Thalidomide29 | 29 | RA, 14; RARS, 4; RAEB, 3; RAEB-t, 5; CMML, 3 | 10 (21) | 14 (7) | 3 (7) | ||
| Arsenic trioxide20 | 101 | Low/Int1, 39; High/Int2, 61 | 11 (0) | 6 (0) | 8 (0) | ||
| Valproic acid30 | 18 | Low, 17; Int1, 55; Int2, 17; High, 11 | 11 (0) | 11 (0) | 6 (0) | ||
. | . | . | % response,*major (minor) . | . | . | ||
|---|---|---|---|---|---|---|---|
| Treatment . | No. patients . | % IPSS/FAB . | HI-E . | % HI-P . | % HI-N . | ||
| Lenalidomide21 | 43 | Low, 51; Int1, 37; Int2, 9; High, 2 | 49 (7) | 10 | 17 | ||
| Darbepoetin alfa24 | 40 | Low, 38; Int1, 52; Int2, 10 | 47 (12) | 0 | 0 | ||
| Antithymocyte immunoglobulin25 | 20 | RA, 65; RARS, 15; RAEB, 20 | 45 (5) | 35 (10) | 10 (5) | ||
| Antithymocyte immunoglobulin26 | 68 | RA, 53; RARS, 4; RAEB, 11 | 67 (20) | 40 (27) | 27 (7) | ||
| Cyclosporine A27 | 50 | Low, 8; Int1, 82; Int2, 10 | 34 (16) | 16 (12) | 22 (4) | ||
| Thalidomide28 | 83 | Low/Int1, 70; High/Int2, 30 | 13 (5) | 0 (1) | 0 | ||
| Thalidomide29 | 29 | RA, 14; RARS, 4; RAEB, 3; RAEB-t, 5; CMML, 3 | 10 (21) | 14 (7) | 3 (7) | ||
| Arsenic trioxide20 | 101 | Low/Int1, 39; High/Int2, 61 | 11 (0) | 6 (0) | 8 (0) | ||
| Valproic acid30 | 18 | Low, 17; Int1, 55; Int2, 17; High, 11 | 11 (0) | 11 (0) | 6 (0) | ||
IWG indicates International Working Group; MDS, myelodysplastic syndromes; IPSS, International Prognostic Scoring System; FAB, French-American-British; HI-E, hematologic improvement, erythroid response; HI-P, hematologic improvement, platelet response; HI-N, hematologic improvement, neutrophil response; Int1, IPSS intermediate-1; Int2, IPSS intermediate-2; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts-CB; RAEB, refractory anemia with excess blasts; CMML, chronic myelomonocytic leukemia.
Some patients achieved responses in more than 1 lineage.